Baotai Biomedical and Taifu Biotech advance three animal antibody drug projects

Baotai Biomedical has joined hands with Taifu Biotech to advance three animal antibody drug projects. Pictured on the right are Song Haolin, Chairman of Baotai, and Sheng Baoxi, Chairman of Taifu Biotechnology, on the left. (Provided by Baotai)

[Reporter Chen Yongji/Taipei Report] Xingkai Biotech (7850), which focuses on the animal market, announced today (5th) that it has established a long-term, multi-project development and manufacturing partnership with Bora Biologics, a biologics commissioned development and manufacturing service (CDMO) under Taifu Biotech (6541). Bora Biologics will support Bora Biologics from process development to process amplification and manufacturing of its antibody animal drug candidate products. The first wave is expected to jointly promote at least three antibody projects, and accelerate the deployment of Baotai's antibody pipeline in the U.S. and global animal health markets through cross-border development and manufacturing cooperation.

Based on this cooperation, Bora Biologics expects to jointly promote at least three antibody projects with Bora Biologics, including two monoclonal antibody projects and one bispecific antibody. This is also the first time that Bora Biologics has extended its biologics development and manufacturing platform to the field of animal medicine. The scope of cooperation covers cell line development, process development, as well as process amplification and manufacturing.

Please read on...

With the aging of pets and unmet medical needs as the main development axis, Baotai Biomedicine adopts a "multi-IP, multi-pipeline layout", scientifically selects development targets with clear clinical needs and market potential, and simultaneously promotes innovative drug pipelines covering areas such as cancer, heart and autoimmune diseases. The antibody drug platform is one of Baotai's core technology platforms. The introduction of international biopharmaceutical CDMO development and manufacturing resources into the three antibody projects not only strengthens the ability of candidate products to move from the research and development stage to process development and large-scale production, but also further establishes Baotai's development and manufacturing foundation in line with international regulatory markets.

Grasp the economic pulse with one hand. Click here to subscribe to Free Finance Youtube channel